Movement Alert|CRISPR Therapeutics AG Falls 5.2% in Regular Trading, Buy-Rating Reiteration Fails to Lift Shares

Market Focus11-17

On November 17, CRISPR Therapeutics AG fell 5.2% in Regular Trading, trading at $40.045 per share, with turnover of $47.3887 million.

The latest identifiable catalyst was an event-driven update: an analyst reiterated a Buy rating and set an $80 price target, but the move did not provide visible support for the shares, with trading still reflecting caution around the pace of commercialization and early-pipeline execution.

Recent company updates show mixed fundamentals and pipeline momentum. The company reported quarterly EPS of $(1.15), missing the $(0.98) consensus estimate, while revenue of $12.669 million beat the $10.495 million estimate. Separately, Casgevy use was described as continuing to grow, and earlier Phase 1b data for CTX310 showed average ANGPTL3 reduction of 65% and triglyceride reduction of 63%, alongside early positive autoimmune data for zugo-cel.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment